• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

    4/28/26 8:35:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company's 2026 annual shareholder meeting in June.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428343333/en/

    If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise.

    If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise.

    Amoo-Gottfried is a seasoned marketing leader with decades of experience helping global transformative brands change how consumers think about their everyday lives. He served as Chief Marketing Officer at DoorDash and in leadership roles at Meta, where he shaped narratives that made the brands category leaders and set the standard for captivating storytelling on an international scale. He has deep experience at some of the world's top marketing agencies, including Leo Burnett, Wieden + Kennedy, and Publicis, where he established the company's first owned agency in Central & West Africa. Amoo-Gottfried also serves on the board of beloved consumer companies, including StitchFix and Vital Farms.

    "Kofi has a wealth of experience in building and growing brands that change what people believe is possible in everything from home delivery to human connection," said Andrew Dudum, CEO and co-founder of Hims & Hers. "At Hims & Hers, we're transforming the everyday health experience by making it simple, deeply personal, and built for real life. Consumers deserve better from their healthcare and, as we continue working to help millions of people around the world feel great, we believe Kofi is an incredibly valuable nominee to join our board."

    "I believe Hims & Hers is on track to be the next company that becomes a daily companion to people everywhere," said Kofi Amoo-Gottfried. "The company's focus on making healthcare not only simple, but a completely reimagined experience, is shifting the entire industry, and I'm honored to be nominated as they begin this next chapter of growth."

    In addition to Amoo-Gottfried, Hims & Hers also nominates the following returning members:

    • Andrew Dudum, CEO of Hims & Hers
    • Deb Autor, former FDA deputy and Chief Policy Officer of Hims & Hers
    • Dr. Toby Cosgrove, former CEO of the Cleveland Clinic
    • Anja Manuel, international regulatory and foreign policy expert
    • Christopher Payne, tech industry leader
    • Andrea Perez, President of FP Movement and former Nike and Sony marketing executive
    • Käre Schultz, former pharmaceutical industry chief
    • David Wells, former CFO of Netflix

    Additionally, the Company and the Board are grateful to Christiane Pendarvis and Dr. Pat Carroll for their many years of dedicated service. Ms. Pendarvis and Dr. Carroll are not up for re-election at the 2026 annual meeting, and the total size of the board will be decreased to 9, effective as of the election of directors at the annual meeting. Dr. Carroll will continue to serve as the company's Global Chief Medical Officer.

    About Hims & Hers Health, Inc

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

    Cautionary Note Regarding Forward-Looking Statements

    This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "anticipates," "expects," "intends," "plans," "decides," "may," "will," "likely," "potential," "future," "coming," "starting," "hope," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the board of directors and the company's future growth. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the results of the shareholder vote at the 2026 annual meeting; changes or developments in the composition of the board of directors; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

    Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of April 28, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260428343333/en/

    Press Contact

    Abby Reisinger-Moley

    press@forhims.com

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    5/12/2026$30.00 → $35.00Buy
    Needham
    4/24/2026$35.00Overweight
    Analyst
    3/10/2026$24.00Sell → Neutral
    Citigroup
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    3/9/2026$30.00Hold → Buy
    Needham
    2/24/2026Buy → Neutral
    BTIG Research
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    More analyst ratings

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Hims & Hers Health with a new price target

    Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $35.00 from $30.00 previously

    5/12/26 10:08:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Analyst initiated coverage on Hims & Hers Health with a new price target

    Analyst initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $35.00

    4/24/26 8:05:39 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    6/2/26 6:02:26 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    5/21/26 5:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    5/19/26 8:17:31 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/26/26 4:48:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Medical Officer Carroll Patrick Harrison

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/26 4:16:21 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Director Wells David B

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/26 4:16:05 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians

    Building on its Canadian launch and the historic introduction of generic semaglutide, Hims & Hers brings the full power of the world's largest consumer health platform — and Juniper's proven track record — to more Canadians than ever Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligible Canadians. By combining Juniper's proven platform with the technology, data, and clinical infrastructure that has advan

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany

    Closing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper's comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims & Hers behind it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602926942/en/Closing brings world-class technology and clinical infrastructu

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform

    The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people Hims & Hers Health, Inc. (NYSE:HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell, Hims & Hers now has a leading presence across the US, UK, Australian, and Canadian markets, with a growing presence in France, Germany, Ireland, Spain, and Japan. Continuing to expand internationally will enable Hims & Hers to lead the next era of digital health, delivering personal, af

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/26/26 4:48:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

    If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company's 2026 annual shareholder meeting in June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428343333/en/If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise. Amoo-Gottfried is a seasoned marketing l

    4/28/26 8:35:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results

    Revenue of approximately $608 million, up 4% year-over-year in Q1 2026 Subscribers grew to nearly 2.6 million, up 9% year-over-year in Q1 2026 Raises full year 2026 revenue guidance1 to a range of $2.8 billion to $3.0 billion and updates Adjusted EBITDA guidance to a range of $275 million to $350 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. Moving forward, the Company plans to transition to an annual rather than quarterly shareholder letter and will continue to provide regular updates through a quarterly earnings call, earnings rele

    5/11/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management

    4/13/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care